Natera (NTRA) has drawn fresh investor attention after a series of partnerships and approvals, including new Phase 3 trial collaborations and regulatory clearance for its Signatera test in Japan for colorectal cancer.

Those clinical partnerships and the Japan approval have coincided with strong momentum in Natera’s stock, with a 30-day share price return of 31.30% and a 1-year total shareholder return of 72.68%. The 3-year total shareholder return is very large and signals that enthusiasm has built over a longer period.

If you are looking for other opportunities in this space, it may be worth checking a screener focused on healthcare and genomics, starting with 40 healthcare AI stocks.

Natera’s recent run, very high 3 year returns and a value score of 2 suggest investors are already paying up for growth. Yet an intrinsic discount of about 49% points the other way, so is there still upside here or is the market already pricing in what comes next?

Most Popular Narrative: 7% Overvalued

The most followed valuation narrative for Natera pegs fair value at about $260.05 compared with the last close of $279.32, framing the current price as richer than that estimate while still anchored in detailed growth and earnings assumptions.

Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long term trends in personalized medicine and early detection, underpinning future revenue expansion.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue trajectory, margin lift, and long run profit multiple are built into that $260.05 fair value? The narrative leans on ambitious growth, a sharp profitability swing, and a premium earnings valuation that sits well above typical biotech expectations. The exact mix of those three ingredients is what really drives the gap to today’s share price.

Result: Fair Value of $260.05 (OVERVALUED)

However, that story can change quickly if reimbursement tightens or key clinical trials for Natera’s MRD and prenatal tests deliver weaker than expected uptake or outcomes.

Another View: SWS DCF Model Points To Undervaluation

Where the analyst narrative for Natera suggests the stock is about 7% overvalued versus a $260.05 fair value, the SWS DCF model points in the opposite direction. On that framework, Natera at $279.32 is trading at roughly a 49% discount to an estimated $543.40 future cash flow value. This raises the question of which set of assumptions you find more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals around Natera, are you comfortable relying on one narrative, or is it time to move quickly, test the assumptions, and weigh both the potential upsides and the flagged concerns for yourself using the 2 key rewards and 1 important warning sign?

Looking for more investment ideas beyond Natera?

If Natera has caught your attention, do not stop there. Broaden your watchlist with other stocks that fit clear, disciplined criteria using the Simply Wall Street Screener.

• Target potential mispricings by scanning for companies that combine quality with attractive valuations using the 43 high quality undervalued stocks.
• Strengthen your focus on resilience by filtering for companies with robust finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot opportunities others might overlook by reviewing the screener containing 18 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.